Study on PGE2 Receptor: Drug Targets and Implications for Disease

Target Name: Prostaglandin EP Receptor

NCBI ID: P26177

Prostaglandin EP Receptor

Other Name(s): EP receptor

Study on PGE2 Receptor: Drug Targets and Implications for Disease

Prostaglandin EP receptor (nonspecified subtype), also known as PGE2 receptor, is a G protein-coupled receptor that plays a crucial role in various physiological processes in the body. It is a key regulator of pain, inflammation, and vascular function, and its Dysfunction has been implicated in numerous diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. As a drug target, the study of PGE2 receptor has become a popular research topic in the pharmaceutical industry, and various compounds have been developed to target this receptor.

The PGE2 receptor is a member of the G protein-coupled receptor family, which includes over 700 different receptors that play a key role in cellular signaling. The PGE2 receptor is a non-selective G protein-coupled receptor, meaning it can interact with a wide range of proteins, including but not limited to G protein-coupled receptors, neurotransmitters, and ion channels. It is expressed in various tissues and cells throughout the body, including the brain, central nervous system, sensory neurons, and endothelial cells.

The PGE2 receptor is involved in the regulation of pain, inflammation, and vascular function. It is a potent mediator of pain perception, and its activation is closely associated with the development of pain. The PGE2 receptor is also involved in the regulation of inflammation, and its inhibition has been shown to have anti-inflammatory effects. Additionally, the PGE2 receptor plays a critical role in the regulation of blood pressure, and its inhibition has been shown to have a positive effect on blood pressure in hypertension.

Due to its involvement in multiple physiological processes, the PGE2 receptor has become a promising drug target. various compounds have been developed to target this receptor, including small molecules, peptides, and agonists. Some of the most well-known compounds include:

1. Atogepant: Atogepant is a selective PGE2 receptor antagonist that is used to treat hypertension. It works by blocking the interaction between the PGE2 receptor and G protein-coupled receptor, which leads to the inhibition of pain perception and the regulation of blood pressure.
2. Urokinase: Urokinase is a peptide that can activate the PGE2 receptor and has been shown to have anti-inflammatory and analgesic effects.
3. Semax: Semax is a small molecule that can activate the PGE2 receptor and has been shown to have analgesic and anti-inflammatory effects.
4. Magainin: Magainin is a peptide that can activate the PGE2 receptor and has been shown to have anti-inflammatory and analgesic effects.
5. Eptinezumab: Eptinezumab is an antibody that can block the interaction between the PGE2 receptor and its ligand, which leads to the inhibition of pain perception.

The PGE2 receptor is also a potential biomarker for several diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. The dysregulation of the PGE2 receptor has been implicated in the development and progression of several diseases, including:

1. Cancer: The PGE2 receptor has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to tumors. Therefore, the dysregulation of the PGE2 receptor has been implicated in the development and progression of cancer.
2. Cardiovascular disease: The PGE2 receptor has been shown to be involved in the regulation of blood pressure, and its dysregulation has been implicated in the development and progression of cardiovascular disease.
3. Neurodegenerative disorders: The PGE2 receptor has

Protein Name: Prostaglandin EP Receptor (nonspecified Subtype)

The "Prostaglandin EP Receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Prostaglandin EP Receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets